Extended growth of AML 1-ETO-expressing cells
Culture . | Source . | Weeks of proliferation . | Growth medium . |
|---|---|---|---|
| AE.1 | CB | 25 | ML |
| AE.2 | CB | 22 | ML |
| AE.4 | PBPC | 20 | ML |
| AE.5 | CB | 17 | ML |
| AE.6.3 | PBPC | 25 | ML |
| AE.6.5 | PBPC | 17 | ML |
| AE.6.8 | PBPC | 17 | ML |
| AE.6.9 | PBPC | 17 | ML |
| AE.6.10 | PBPC | 17 | ML |
| AE.6.11 | PBPC | 17 | ML |
| AE.6.12 | PBPC | 20 | ML |
| AE.9 | CB | 30 | ML and SF |
| AE.11 | CB | 32 | ML and SF |
| AE.11.1 | CB | 29 | ML |
| AE.11.2 | CB | 22 | ML |
| AE.11.3 | CB | 21 | SF |
| AE.11.4 | CB | 23 | SF |
| AE.11.5 | CB | 21 | SF |
Culture . | Source . | Weeks of proliferation . | Growth medium . |
|---|---|---|---|
| AE.1 | CB | 25 | ML |
| AE.2 | CB | 22 | ML |
| AE.4 | PBPC | 20 | ML |
| AE.5 | CB | 17 | ML |
| AE.6.3 | PBPC | 25 | ML |
| AE.6.5 | PBPC | 17 | ML |
| AE.6.8 | PBPC | 17 | ML |
| AE.6.9 | PBPC | 17 | ML |
| AE.6.10 | PBPC | 17 | ML |
| AE.6.11 | PBPC | 17 | ML |
| AE.6.12 | PBPC | 20 | ML |
| AE.9 | CB | 30 | ML and SF |
| AE.11 | CB | 32 | ML and SF |
| AE.11.1 | CB | 29 | ML |
| AE.11.2 | CB | 22 | ML |
| AE.11.3 | CB | 21 | SF |
| AE.11.4 | CB | 23 | SF |
| AE.11.5 | CB | 21 | SF |
Summary of 7 independent experiments, performed essentially as described in Figure 1. Growth media consisted of IMDM with 20% FBS and 7 cytokines (ML) or 5 cytokines in a serum-free media (SF). Experiments 6 and 11 (using PBPCs or cord blood [CB], respectively) involved splitting cultures into subcultures.